Citations

Clear

382 citation(s) found for "Shapiro, R".

Utility of Dobutamine Stress Echocardiography as Part of the Pre‐Liver Transplant Evaluation: An Evaluation of Its Efficacy
Snipelisky, David , Levy, Michael , Shapiro, Brian P.

Mayo Clinic

Clinical Cardiology | April 9, 2014 | Volume: 37 | Issue: 8 | Pages: 468-472

10.1002/clc.22283 | PMID 24719365 Get It

ABSTRACTBackgroundDobutamine stress echocardiography (DSE) is commonly used to risk stratify patients in the cardiac evaluation prior to orthotopic liver transplantation (OLT). Data remain limited regarding the accuracy to predict obstructive coronary artery disease (CAD) using this approach.HypothesisWe hypothesize that DSE may have limitations in the investigation of underlying CAD in patients with end‐stage liver disease.MethodsA retrospective chart review of all patients who underwent OLT at Mayo Clinic in Florida between 1998 and 2010 was performed. Sixty‐six underwent invasive coronary angiography (ICA) within 1 year of DSE and were included in our study. Based on DSE results, patients were stratified into 1 of 3 groups: nonischemic, ischemic, and indeterminate. The relationship between DSE, ICA, and death from all cause and cardiac‐related cause with a minimum 3‐year follow‐up period were analyzed.ResultsA total of 66 patients were included in our cohort. There was no difference in age, gender, severity of liver disease, and echocardiographic findings among the groups. Forty‐three percent of patients (n = 12) with an abnormal result on DSE were found to have moderate or severe obstructive CAD on cardiac catheterization, whereas 49% of patients (n = 17) with a normal finding on DSE had moderate or severe CAD. Of 5 patients who died from a documented cardiac etiology, 3 had normal stress test results, 1 had abnormal findings, and 1 had an indeterminate DSE result. When compared with ICA, our study demonstrated that DSE has a sensitivity of 41.4% (95% confidence interval [CI]: 0.24‐0.61), specificity of 47.1% (95% CI: 0.30‐0.65), positive predictive value of 40.0% (95% CI: 0.23‐0.59), and negative predictive value of 48.0% (95% CI: 0.31‐0.66) in identification of underlying CAD.ConclusionsAlthough widely used, DSE may not always accurately reflect the severity of obstructive CAD in patients undergoing OLT.
Cardiac Mri As a Diagnostic Tool in Pulmonary Hypertension
Alassas, Khadija, Mergo, Patricia J. , Safford, Robert E. , Parikh, Pragnesh , Shapiro, Brian P. , Ibrahim, El‐Sayed H. , Burger, Charles D.

Mayo Clinic

Future Cardiology | December 18, 2013 | Volume: 10 | Issue: 1 | Pages: 117-130

10.2217/fca.13.97 | PMID 24344668 Get It

Cyclic Bicytopenia in a Patient with Shapiro Syndrome
Roeker, Lindsey E. , Gupta, Vinay , Wolanskyj, Alexandra P., Gangat, Naseema , Gonsalves, Wilson I. , Roeker, Lindsey

Mayo Clinic

Case Reports in Hematology | September 25, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-4

10.1155/2013/231713 | PMID 24187634 Get It

Shapiro syndrome and periodic hypothermia have been reported approximately fifty times in the literature. Shapiro syndrome is defined as the constellation of periodic hypothermia and hyperhidrosis along with agenesis of the corpus callosum by Shapiro et al. in 1969. Periodic hypothermia is a more broad diagnosis with a number of proposed mechanisms; it occurs in patients without structural brain abnormalities. Hematologic abnormalities beyond iron-deficiency anemia have not been documented in any of the reported cases of Shapiro syndrome or periodic hypothermia. Though accidental and therapeutic hypothermia have been associated with thrombocytopenia, this is, to our knowledge, the first reported case of periodic intrinsic hypothermia causing bicytopenia. In this report, we present the case of a patient with Shapiro syndrome who experienced cyclic bicytopenia mirroring hypothermic episodes. We address the differential diagnosis of bicytopenia, review the mechanisms proposed for cytopenias related to hypothermia, and propose possible mechanisms for the finding in this case.
Advances of Cardiovascular MRI in Hypertrophic Cardiomyopathy
Blackshear, Joseph L., Mergo, Patricia J. , Parikh, Pragnesh , Batton, Kyle A., Shapiro, Brian P. , Kumar, Preetham, Kumar, Preetham , Ibrahim, El‐Sayed H.

Mayo Clinic

Future Cardiology | September 11, 2013 | Volume: 9 | Issue: 5 | Pages: 697-709

10.2217/fca.13.58 | PMID 24020671 Get It

Minimal effect of bortezomib in reducing anti‐pig antibodies in human leukocyte antigen‐sensitized patients: a pilot study
Bentall, Andrew , Long, Cassandra , Fang, Jason, Andreyev, Oleg , Lunz, John G., Ezzelarab, Mohamed , Abu‐Elmagd, Kareem , Shapiro, Ron , Ayares, David , Stegall, Mark D. , Hara, Hidetaka , Ezzelarab, Mohamed B. , Cooper, David K. C. , Stegall, Mark D , Bentall, Andrew

Mayo Clinic

Xenotransplantation | September 3, 2013 | Volume: 20 | Issue: 6 | Pages: 429-437

10.1111/xen.12052 | PMID 23998233 Get It

AbstractBackgroundBortezomib, a proteasome inhibitor used to treat multiple myeloma, has been administered (± plasma exchange ± intravenous immunoglobulin [IVIg]) in attempts to reduce antibodies against human leukocyte antigens (HLA) in sensitized patients undergoing organ transplantation. To our knowledge, bortezomib has not been investigated for its effect on natural anti‐pig antibodies. If bortezomib could reduce the production of anti‐pig antibodies, this would likely be beneficial to the outcome of pig organ grafts in primates.MethodsNine patients received bortezomib either to reduce anti‐HLA antibody levels before organ allotransplantation or to treat antibody‐mediated rejection. Patients at the Mayo Clinic (Group 1; n = 4) received bortezomib alone, whereas at the UPMC (Group 2; n = 5), this was combined with plasmaphereses ± IVIg in some cases. Anti‐pig IgM and IgG levels against wild‐type (WT) and α1,3‐galactosyltransferase gene knockout (GTKO) pig aortic endothelial cells (flow cytometry—relative mean fluorescence intensity) and anti‐Gal IgM and IgG (ELISA–OD480 nm) were measured pre‐ and post‐bortezomib therapy.ResultsMean anti‐pig IgM levels were 11.2 (WT) and 1.9 (GTKO) pre‐bortezomib treatment and 9.4 (WT: P = 0.02) and 1.7 (GTKO: P = 0.33) post‐bortezomib treatment, respectively. Mean anti‐pig IgG levels were 4.3 (WT) and 1.5 (GTKO) pre‐bortezomib treatment and 3.6 (WT: P = 0.21) and 1.4 (GTKO: P = 0.20) post‐bortezomib treatment, respectively. Mean anti‐Gal IgM and IgG levels were 0.7 and 1.1, respectively, pre‐treatment, and 0.6 (P = 0.03) and 1.1 (NS), respectively, post‐treatment. When the data were analyzed in Groups 1 and 2 separately, there were no significant differences between the pre‐ and post‐bortezomib levels of anti‐pig, anti‐non‐Gal, or anti‐Gal IgM or IgG.ConclusionsFrom this limited study, we conclude that bortezomib might reduce anti‐Gal IgM levels in primates, but, in this respect alone, is unlikely to have any significant effect on the outcome of GTKO pig organ transplantation.
Cardiac Troponin Elevation Predicts Mortality in Patients Undergoing Orthotopic Liver Transplantation
Snipelisky, David , Donovan, Sean, Levy, Michael , Satyanarayana, Raj, Shapiro, Brian P.

Mayo Clinic

Journal of Transplantation | July 14, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-6

10.1155/2013/252838 | PMID 23956840 Get It

Introduction. While patients undergoing orthotopic liver transplantation (OLT) have high cardiovascular event rates, preoperative risk stratification may not necessarily predict those susceptible patients. Troponin T (TnT) may help predict patients at risk for cardiovascular complications.Methods. Consecutive patients undergoing OLT at Mayo Clinic in Florida between 1998 and 2010 who had TnT obtained within 10 days following surgery were included. Three groups were compared based on TnT level: (1) normal (TnT≤0.01 ng/mL), (2) intermediate (TnT 0.02–0.11 ng/mL), and (3) elevated (TnT>0.11 ng/mL). Overall and cardiovascular mortality was assessed.Results. Of the 78 patients included, there was no difference in age, gender, severity of liver disease, and echocardiographic findings. Patients in the normal and intermediate TnT groups had a lower overall mortality rate (14.3% and 0%, resp.) when compared with those with elevated TnT (50%;P=0.001). Patients in the elevated TnT group had a cardiovascular mortality rate of 37.5% compared with 1.4% in the other groups combined (P<0.01). The elevated TnT group had a much higher mortality rate when compared with those in the intermediate group (P<0.0001).Conclusion. TnT may accurately help risk stratify patients in the early postoperative setting to better predict cardiovascular complications.
Hoxa9 and Flt3 Signaling Synergistically Regulate an Early Checkpoint in Lymphopoiesis
Gwin, Kimberly, Shapiro, Mariya B. , Dolence, Joseph J., Huang, Zhixin , Medina, Kay L. , Gwin, Kimberly A

Mayo Clinic

The Journal of Immunology | June 15, 2013 | Volume: 191 | Issue: 2 | Pages: 745-754

10.4049/jimmunol.1203294 | PMID 23772038 Get It

Abstract Hoxa9 and Flt3 signaling are individually important for the generation of lymphoid lineage precursors from multipotent hematopoietic progenitors (MPP) in bone marrow. Mice deficient for Hoxa9, Flt3, or Flt3 ligand (FL) have reduced numbers of lymphoid-primed multipotential progenitors (LMPP), common lymphoid progenitors (CLP), and B/T cell precursors. Hoxa9 regulates lymphoid development, in part, through transcriptional regulation of Flt3. However, it was unclear whether Hoxa9 has functions in lymphopoiesis independent of, or alternatively, synergistically with Flt3 signaling. In this study, we show that Hoxa9−/−Flt3l−/− mice have more severe deficiencies in all B lineage cells, CLP, LMPP, and total Flt3+ MPP in bone marrow than the single knockouts. Although LMPP and Flt3+ CLP contain precursors for NK and dendritic cell lineage cells, no deficiencies in these lineages beyond that in Flt3l−/− mice was found. Thymocyte cellularity was significantly reduced in the compound knockout, although peripheral T cell numbers mirrored Flt3l−/− mice. Analysis of the hematopoietic progenitor compartment revealed elevated numbers of CD150+hiCD34−CD41+ myeloid–biased stem cells in Hoxa9−/−Flt3l−/− mice. In contrast, CD150− MPP enriched for lymphoid potential were synergistically reduced, suggesting Hoxa9 and Flt3 signaling function coordinately to regulate lymphopoiesis at a very early stage. Real-time PCR analysis of CD150−Flt3+ cells from wild-type control, Hoxa9−/−, and Flt3l−/− single knockouts revealed decreased lymphoid transcripts, corroborating the importance of these regulators in lymphoid development. Taken together, these studies reveal a very early checkpoint in lymphopoiesis dependent on the combinatorial activities of Hoxa9 function and Flt3 signaling.
Therapy of Digestive Disorders: A Companion to Sleisenger and Fortran's Gastroenterological and Liver Disease
Shapiro, Michael S.

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 133 | Issue: 8 | Pages: 660

10.7326/0003-4819-133-8-200010170-00030 | PMID 11033608 Get It

A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
Holkova, Beata , Supko, Jeffrey G. , Ames, Matthew M. , Shapiro, Geoffrey I. , Perkins, Edward Brent, Ramakrishnan, Viswanathan , Tombes, Mary Beth, Honeycutt, Connie, McGovern, Renee M., Shrader, Ellen, Wellons, Martha D., Sankala, Heidi, Doyle, Austin, Wright, John, Roberts, John D. , Reid, Joel M. , Kmieciak, Maciej , Wright, John, Grant, Steven , Shapiro, Geoffrey I

Mayo Clinic

Clinical Cancer Research | March 20, 2013 | Volume: 19 | Issue: 7 | Pages: 1873-1883

10.1158/1078-0432.ccr-12-2926 | PMID 23515411 Get It

Abstract Purpose: This phase I study was conducted to identify the maximum-tolerated dose (MTD) of alvocidib when combined with vorinostat in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Secondary objectives included investigating the pharmacokinetic and pharmacodynamic effects of the combination. Experimental Design: Patients received vorinostat (200 mg orally, three times a day, for 14 days) on a 21-day cycle, combined with 2 different alvocidib administration schedules: a 1-hour intravenous infusion, daily × 5; or a 30-minute loading infusion followed by a 4-hour maintenance infusion, weekly × 2. The alvocidib dose was escalated using a standard 3+3 design. Results: Twenty-eight patients were enrolled and treated. The alvocidib MTD was 20 mg/m2 (30-minute loading infusion) followed by 20 mg/m2 (4-hour maintenance infusion) on days one and eight, in combination with vorinostat. The most frequently encountered toxicities were cytopenias, fatigue, hyperglycemia, hypokalemia, hypophosphatemia, and QT prolongation. Dose-limiting toxicities (DLT) were cardiac arrhythmia-atrial fibrillation and QT prolongation. No objective responses were achieved although 13 of 26 evaluable patients exhibited stable disease. Alvocidib seemed to alter vorinostat pharmacokinetics, whereas alvocidib pharmacokinetics were unaffected by vorinostat. Ex vivo exposure of leukemia cells to plasma obtained from patients after alvocidib treatment blocked vorinostat-mediated p21CIP1 induction and downregulated Mcl-1 and p-RNA Pol II for some specimens, although parallel in vivo bone marrow responses were infrequent. Conclusions: Alvocidib combined with vorinostat is well tolerated. Although disease stabilization occurred in some heavily pretreated patients, objective responses were not obtained with these schedules. Clin Cancer Res; 19(7); 1873–83. ©2013 AACR.